Structure of light hypernuclei and Λ–nuclear interaction

2001 ◽  
Vol 684 (1-4) ◽  
pp. 586-588 ◽  
Author(s):  
R. Sinha ◽  
Q.N. Usmani
2019 ◽  
Vol 199 ◽  
pp. 01014
Author(s):  
K. Piscicchia ◽  
M. Bazzi ◽  
G. Belloti ◽  
A. M. Bragadireanu ◽  
D. Bosnar ◽  
...  

The AMADEUS experiment at the DAΦNE collider of LNF-INFN deals with the investigation of the at-rest, or low-momentum, K− interactions in light nuclear targets, with the aim to constrain the low energy QCD models in the strangeness sector. The 0 step of the experiment consisted in the reanalysis of the 2004/2005 KLOE data, exploiting K− absorptions in H, 4He, 9Be and 12C, leading to the first invariant mass spectroscopic study with very low momentum (about 100 MeV) in-flight K− captures. With AMADEUS step 1 a dedicated pure Carbon target was implemented in the central region of the KLOE detector, providing a high statistic sample of pure at-rest K− nuclear interaction. The first measurement of the non-resonant transition amplitude $\left| {{A_{{K^ - }n \to \Lambda {\pi ^ - }}}} \right|$ at $\sqrt s = 33\,MeV$ below the K̄N threshold is presented, in relation with the Λ(1405) properties studies. The analysis procedure adopted in the serarch for K− multi-nucleon absorption cross sections and Branching Ratios will be also described.


2020 ◽  
Vol 2020 (9) ◽  
Author(s):  
Patrick Draper ◽  
Jonathan Kozaczuk ◽  
Scott Thomas

Abstract A primary goal of a future e+e− collider program will be the precision measurement of Higgs boson properties. For practical reasons it is of interest to determine the minimal set of detector specifications required to reach this and other scientific goals. Here we investigate the precision obtainable for the e+e−Zhμ+μ−X inclusive cross section and the Higgs boson mass using the di-muon recoil method, considering a detector that has only an inner tracking system within a solenoidal magnetic field, surrounded by many nuclear interaction lengths of absorbing material, and an outer muon identification system. We find that the sensitivity achievable in these measurements with such a tracking detector is only marginally reduced compared to that expected for a general purpose detector with additional electromagnetic and hadronic calorimeter systems. The difference results mainly from multi-photon backgrounds that are not as easily rejected with tracking detectors. We also comment on the prospects for an analogous measurement of the e+e−→Zh→e+e−X inclusive cross section. Finally, we study searches for light scalars utilizing the di-muon recoil method, estimating the projected reach with a tracking or general purpose detector.


1951 ◽  
Vol 82 (1) ◽  
pp. 105-106 ◽  
Author(s):  
G. Bernardini ◽  
E. T. Booth ◽  
L. Lederman ◽  
J. Tinlot

2005 ◽  
Vol 206 (1) ◽  
pp. 35-46 ◽  
Author(s):  
Joanna Trojanek ◽  
Sidney Croul ◽  
Thu Ho ◽  
Jin Ying Wang ◽  
Armine Darbinyan ◽  
...  

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Junjie Xu ◽  
Lin Ji ◽  
Yuelong Liang ◽  
Zhe Wan ◽  
Wei Zheng ◽  
...  

AbstractSorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular RNA, circRNA-SORE (a circular RNA upregulated in sorafenib-resistant HCC cells), plays a significant role in sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and depletion of circRNA-SORE substantially increases the cell-killing ability of sorafenib. Further studies revealed that circRNA-SORE binds the master oncogenic protein YBX1 in the cytoplasm, which prevents YBX1 nuclear interaction with the E3 ubiquitin ligase PRP19 and thus blocks PRP19-mediated YBX1 degradation. Moreover, our in vitro and in vivo results suggest that circRNA-SORE is transported by exosomes to spread sorafenib resistance among HCC cells. Using different HCC mouse models, we demonstrated that silencing circRNA-SORE by injection of siRNA could substantially overcome sorafenib resistance. Our study provides a proof-of-concept demonstration for a potential strategy to overcome sorafenib resistance in HCC patients by targeting circRNA-SORE or YBX1.


2009 ◽  
Vol 508 (1) ◽  
pp. 1-7 ◽  
Author(s):  
V. A. Dogiel ◽  
V. Tatischeff ◽  
K. S. Cheng ◽  
D. O. Chernyshov ◽  
C. M. Ko ◽  
...  

1990 ◽  
Vol 191 (6) ◽  
pp. 351-408 ◽  
Author(s):  
R. Silberberg ◽  
C.H. Tsao

Sign in / Sign up

Export Citation Format

Share Document